Israel
Clexio Biosciences is a CNS-first clinical-stage pharmaceutical company that is dedicated to making life worth living again for millions of patients. The company's therapies are designed to address unmet needs through the integration of drugs with innovative technologies. Clexio’s pipeline focuses on developing safe and effective treatments with rapid onset of action for a range of neurological and psychiatric conditions, including Major Depressive Disorder, Parkinson’s Disease, Pain, and other conditions involving neurological system impairment.
The company emphasizes placing patients and their conditions at the core of its mission and aims to help patients regain a sense of balance, health, and a life worth living. Founded in 2018, Clexio Biosciences operates in the Biotechnology, Health Care, and Pharmaceutical sectors. With a multi-disciplinary team, the company has vast experience in drug development and views its team and partners as crucial to its success.
Clexio Biosciences presents an opportunity for venture capitalists to join a vision aimed at improving the lives of millions of patients. It is a company to watch in the biopharmaceutical industry as it continues to pursue innovative solutions for neurological and psychiatric conditions.
